Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.

@article{Probstfield2015DesignOF,
  title={Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.},
  author={Jeffrey Lynn Probstfield and Irl B. Hirsch and Kevin O'Brien and Barry R. Davis and Richard M. Bergenstal and Connie Kingry and Dori Khakpour and Sarah Pressel and Kelley R H Branch and Matthew C Riddle},
  journal={Diabetes care},
  year={2015},
  volume={38 8},
  pages={1558-66}
}
OBJECTIVE Glycemic variability may contribute to adverse medical outcomes of type 2 diabetes, but prior therapies have had limited success in controlling glycemic fluctuations, and the hypothesis has not been adequately tested. RESEARCH DESIGN AND METHODS People with insulin-requiring type 2 diabetes and high cardiovascular risk were enrolled during a run-in period on basal-bolus insulin (BBI), and 102 were randomized to continued BBI or to basal insulin with a prandial GLP-1 receptor agonist… CONTINUE READING